ArticlePLoS neglected tropical diseases2019
Economic burden of dengue in Indonesia.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The economic burden of dengue: a systematic literature review of unit costs for non-fatal episodes treated in the formal healthcare system.BMC infectious diseases · 2026Pooled it
- Productivity costs from a dengue episode in Asia: a systematic literature review.BMC infectious diseases · 2020Pooled it
- Cross-cultural adaptation and psychometric evaluation of the dengue preventive attitudes questionnaire for Indonesian public health nurses.BMC nursing · 2026Article
- Understanding the epidemiological trends and economic impact of dengue in Indonesia: A systematic literature review.IJID regions · 2026Review
- Enhancing Entomological Surveillance to CombatJournal of tropical medicine · 2026Article
- Article
- Early intervention of 5% albumin shown superior control of vascular integrity and function compared to ringer's lactatein hospitalized adult with grade I & II Dengue hemorrhagic fever: a multicenter randomized controlled trial in Indonesia.Tropical diseases, travel medicine and vaccines · 2024Article
- Estimating dengue disease and economic burden to inform municipal-level policymakers: Method for a pragmatic city-level observational cohort study.Gates open research · 2024Observational
- Economic burden of dengue in urban Bangladesh: A societal perspective.PLoS neglected tropical diseases · 2023Article
- Integrated systems immunology approach identifies impaired effector T cell memory responses as a feature of progression to severe dengue fever.Journal of biomedical science · 2023Article
- Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia.PLoS neglected tropical diseases · 2021Article
- Economic and disease burden of Japanese encephalitis in Zhejiang Province, 2013-2018.PLoS neglected tropical diseases · 2021Article
- Assessment of Mosquito Collection Methods for Dengue Surveillance.Frontiers in medicine · 2021Article
- Cost of Dengue Illness in Indonesia across Hospital, Ambulatory, and not Medically Attended Settings.The American journal of tropical medicine and hygiene · 2020Article
- Point-of-care thrombocyte function testing using multiple-electrode aggregometry in dengue patients: an explorative study.BMC infectious diseases · 2020Article
- Untapped Potential: A Qualitative Study of a Hospital-Based Dengue Surveillance System.The American journal of tropical medicine and hygiene · 2020Article
- Cost-Effectiveness of Dengue Vaccination in Indonesia: Considering Integrated Programs withInternational journal of environmental research and public health · 2020Article
- Evaluation of Health Information System (HIS) in The Surveillance of Dengue in Indonesia: Lessons from Case in Bandung, West Java.International journal of environmental research and public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue is associated with significant economic expenditure and it is estimated that the Asia Pacific region accounts for >50% of the global cost. Indonesia has one of the world's highest dengue burdens; Aedes aegypti and Aedes albopictus are the primary and secondary vectors. In the absence of local data on disease cost, this study estimated the annual economic burden during 2015 of both hospitalized and ambulatory dengue cases in Indonesia.
methodsTotal 2015 dengue costs were calculated using both prospective and retrospective methods using data from public and private hospitals and health centres in three provinces: Yogyakarta, Bali and Jakarta. Direct costs were extracted from billing systems and claims; a patient survey captured indirect and out-of-pocket costs at discharge and 2 weeks later. Adjustments across sites based on similar clinical practices and healthcare landscapes were performed to fill gaps in cost estimates. The national burden of dengue was extrapolated from provincial data using data from the three sites and applying an empirically-derived epidemiological expansion factor.
resultsTotal direct and indirect costs per dengue case assessed at Yogyakarta, Bali and Jakarta were US$791, US$1,241 and US$1,250, respectively. Total 2015 economic burden of dengue in Indonesia was estimated at US$381.15 million which comprised US$355.2 million for hospitalized and US$26.2 million for ambulatory care cases.
conclusionDengue imposes a substantial economic burden for Indonesian public payers and society. Complemented with an appropriate weighting method and by accounting for local specificities and practices, these data may support national level public health decision making for prevention/control of dengue in public health priority lists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.